Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection
1218  

Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection

AbbVie’s new pangenotypic regimen combining glecaprevir and pibrentasvir cured almost all HIV-positive people with hepatitis C co-infection in the EXPEDITION-2 study, according to a presentation on Monday at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris. Glecaprevir/pibrentasvir (Maviret) is expected to be approved ...

July 26, 2017
EATG  News  
Lay Summaries workshop: Report now out!
994  

Lay Summaries workshop: Report now out!

23.07.2017 The results from clinical trials are usually discussed within the scientific community only and are seldom spread to the general public. With the release of the EU Clinical Trials Regulation 536/2014 in 2014, informing the public about clinical trial results will become mandatory in Europe. Lay ...

July 24, 2017
EATG  News  
MPP video: Working together for better treatment options
853  

MPP video: Working together for better treatment options

The Medicines Patent Pool (MPP) released a short film, in which MPP’s stakeholders from industry, government, civil society and patient groups discuss the foundation’s innovative business model, achievements and future plans to increase access to HIV, hepatitis C and TB treatment within the context of ...

May 25, 2017
EATG  News  
Recurrent TB and associated factors in Uzbekistan
889  

Recurrent TB and associated factors in Uzbekistan

Recurrent TB and associated factors: A five-year countrywide study in Uzbekistan Abstract Background In Uzbekistan, despite stable and relatively high tuberculosis treatment success rates, relatively high rates of recurrent tuberculosis have recently been reported. Recurrent tuberculosis is when a patient who was treated for pulmonary tuberculosis and cured, ...

May 15, 2017
EATG  News  
Webinar series on the Global Ministerial Conference on TB
1132  

Webinar series on the Global Ministerial Conference on TB

Treatment Action Group and the ACTION Global Health Advocacy Partnership will host a 2-part webinar series on civil society asks and engagement ahead of the Global Ministerial Conference on TB to be held on 16–17 November 2017 in Moscow, Russian Federation. The two webinars will take ...

May 12, 2017
EATG  News  
HIV: ART has added 10 years to lives of first-world patients
871  

HIV: ART has added 10 years to lives of first-world patients

Antiretroviral therapy (ART) has increased life expectancy by a decade in young Europeans and North Americans treated for HIV. Substantial declines in mortality emerged especially for those starting treatment between 2008 and 2010, pointing to the positive effect of evolving therapies and earlier detection. Reporting in ...

May 12, 2017
EATG  News  
Webinar with WHO on hormonal contraception and HIV
898  

Webinar with WHO on hormonal contraception and HIV

AVAC will host a webinar on the newly released WHO guidance on hormonal contraceptive eligibility for women at high risk of HIV on 26 April 2017. [gview file="http://ecuo.org/mvdev/wp-content/uploads/sites/4/2017/04/hc_HIV_guidance_March2017.pdf"] For more information about the webinar and how to register, click here. Sources

April 20, 2017
EATG  News